You are here

ALS

Biogen Shares Positive Data on Phase I/II Trial of Tofersen for SOD1-ALS

Biogen Shares Positive Data on Phase I/II Trial of Tofersen for SOD1-ALS

BioSpace

clinical trials

Flag link:

Amylyx Pharmaceuticals nabs $30M for ALS, Alzheimer's work

Amylyx Pharmaceuticals nabs $30M for ALS, Alzheimer's work

Fierce Biotech

Amylyx Pharmaceuticals

Alzheimer's disease

Flag link:

Yumanity and Merck Ink $500 Million+ Deal for Neurodegenerative Diseases

Yumanity and Merck Ink $500 Million+ Deal for Neurodegenerative Diseases

BioSpace

Yumanity Therapeutics

frontotemporal lobar dementia

Flag link:

After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug

After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug

BioSpace

Denali Therapeutics

Alzheimer's disease

clinical trials

Flag link:

Amgen-backed QurAlis Snags $42 Million in Series A to Develop ALS Treatments

Amgen-backed QurAlis Snags $42 Million in Series A to Develop ALS Treatments

BioSpace

Flag link:

I Have a Dream… Five Dreams for Biotech

I Have a Dream… Five Dreams for Biotech

BioSpace

Alzheimer's disease

Flag link:

Alexion to Start Pivotal Study on Ultomiris for ALS in Q1

Alexion to Start Pivotal Study on Ultomiris for ALS in Q1

Yahoo/Zacks.com

clinical trials

Flag link:

First-of-its-kind trial in ALS spurs hope for brutal disease

First-of-its-kind trial in ALS spurs hope for brutal disease

BioPharma Dive

clinical trials

Implicit Bioscience

Prilenia Therapeutics

Clene Nanomedicine

Flag link:

5 years later, Ice Bucket Challenge's impact on drug research still unfolding

5 years later, Ice Bucket Challenge's impact on drug research still unfolding

Bizjournals

drug development

Flag link:

In another disappointment for investors, FDA slaps down Biohaven’s revised version of an old ALS drug

In another disappointment for investors, FDA slaps down Biohaven’s revised version of an old ALS drug

Endpoints

Flag link:

Mallinckrodt Halts Midstage ALS Trial Over Safety Concerns

Mallinckrodt Halts Midstage ALS Trial Over Safety Concerns

BioSpace

clinical trials

H.P. Acthar Gel

Flag link:

Biogen’s Experimental Drug Shows Promise for Genetic Form of ALS

Biogen’s Experimental Drug Shows Promise for Genetic Form of ALS

BioSpace

Ionis Pharmaceuticals

Flag link:

Cytokinetics' comeback attempt with second-gen drug is slammed by a PhII failure in ALS

Cytokinetics' comeback attempt with second-gen drug is slammed by a PhII failure in ALS

Endpoints

clinical trials

Flag link:

Biogen’s antisense ALS drug shows promise in early clinical trial

Biogen’s antisense ALS drug shows promise in early clinical trial

Fierce Biotech

clinical trials

Flag link:

Research Roundup: New CRISPR, ALS, Colon Cancer, Asthma and More

Research Roundup: New CRISPR, ALS, Colon Cancer, Asthma and More

BioSpace

Flag link:

ALS researchers at Harvard uncover new biomarker and drug target

ALS researchers at Harvard uncover new biomarker and drug target

Fierce Biotech

Lou Gehrig's disease

Flag link:

Biogen opts in for Ionis' ALS candidate, plans pivotal trial

Biogen opts in for Ionis' ALS candidate, plans pivotal trial

BioCentury

Ionis Pharmaceuticals

Flag link:

Researchers Cure ALS in Laboratory Animals Using Gene Therapy

Researchers Cure ALS in Laboratory Animals Using Gene Therapy

BioSpace

Lou Gehrig's disease

University of California

Flag link:

PARP inhibitors show promise for treating ALS and other brain disorders

PARP inhibitors show promise for treating ALS and other brain disorders

Fierce Biotech

PARP inhibitors

Flag link:

Orion takes repurposed heart failure drug into phase 3 for ALS

Orion takes repurposed heart failure drug into phase 3 for ALS

Fierce Biotech

clinical trials

Flag link:

Pages